TAS-102(35mg/m2) is administered orally twice daily in 1-5days and 15-20 days and Bevacizumab(5mg/kg) is administered by injection in day 1 and day15. 1 cycle is 28days.
Sponsors
Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery, Surgical Oncology Association in Chiba (SOAC)
Conditions
Colorectal Cancer
Phase 2
Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine
RecruitingJPRN-UMIN000026043
Start: 2016-03-08Target: 28Updated: 2026-06-29
TAS-102 and Bevacizumab as salvage line chemotherapy for colorectal cancer
Active, not recruitingJPRN-UMIN000031790
Start: 2019-03-20Target: 45Updated: 2026-06-29